LncRNA Information | ||||||
---|---|---|---|---|---|---|
ID | EL0822 | Name | LOC105246506 | Aliases | N/A | |
Species | Mus musculus | Chromosome | 18 | Start site | 80186239 | |
End site | 80193569 | Chain | plus | Exon NO. | 5 | |
Assembly | GRCm38.p4 | Class | N/A | NCBI accession | NR_131039 | |
Ensembl | N/A | Sequence |
Function (not disease relevant) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Methods | Sample/condition | Expression pattern | Dysfunction type | Description | PMID | Source | |||
combined full-length mESC transcriptome genomic mapping data with chromatin immunoprecipitation genomic location maps of the key mESC transcription factors | mouse embryonic stem cells (mESCs) | N/A | Interaction | potential roles in pluripotency | 20026622 | ||||
in vitro knowdown, qRT-PCR | mESC (mouse embryonic stem cells), MSC (mice mesenchymal stem cells) | up-regulated | interaction | AK141205 positively promoted CXCL13 expression via acetylation of H4 histone in the promoter region;In summary, we report a completely novel role of AK141205/CXCL13 as a regulator of OGP-induced osteogenic differentiation of SMCs. Our finding provides a potential therapeutic targeting of AK141205 for enhancing disease-treatment effect of SMCs. (PMID:26321662). When overexpressed, AK141205 led to an increase in Oct4 mRNA and to a corresponding up-regulation of endodermal markers, in addition to initiating meso- and ectodermal differentiation. (PMID:20026622). | 26321662; 20026622 | ||||
Interaction | |||||||||
---|---|---|---|---|---|---|---|---|---|
Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
Nanog | DNA-TF | regulation | AK141205 is repressed by the transcription factor Nanog. | 20026622 | LncRNADisease | ||||
Oct4 and Nanog | RNA-DNA | binding | AK028326 (Oct4-activated) and AK141205 (Nanog-repressed), are direct targets of Oct4 and Nanog. | 20026622 | |||||
CXCL13; Nanog | RNA-Protein | regulation | Analysis of CXCL13 expression in SMCs(pcDNA-AK141205) revealed that AK141205 positively promoted CXCL13 expression via acetylation of H4 histone in the promoter region (co-expression); Nanog may directly repress transcription of lncRNA AK141205 (regulation). | 26321662; 20026622 | |||||